From Novartis, Bristol MS meds to new ADCs, here are 2020’s blockbuster drug launches

From Novartis, Bristol MS meds to new ADCs, here are 2020's blockbuster drug launches

Special Reports The 10 most-anticipated drug launches of 2020

Special Reports The 10 most-anticipated drug launches of 2020

Η Bristol-Myers Squibb ολοκλήρωσε την εξαγορά της Celgene

Κάντε like στη σελίδα μας στο facebook για να μαθαίνετε πρώτοι όλα τα νέα!!    Η Bristol-Myers Squibb ανακοίνωσε την ολοκλήρωση της εξαγοράς της Celgene κατόπιν λήψης της ρυθμιστικής έγκρισης από όλες τις αρμόδιες κρατικές αρχές, καθώς και της έγκρισης των μετόχων της Bristol-Myers Squibb και της Celgene, η οποία είχε ανακοινωθεί στις 12 Απριλίου … Συνεχίστε να διαβάζετε Η Bristol-Myers Squibb ολοκλήρωσε την εξαγορά της Celgene.

Biopharma in 2019

Biopharma in 2019

Promising rare conditions treatments could upend the market hierarchy

Promising rare conditions treatments could upend the market hierarchy

Why Celgene Is Looking Less Risky and More Attractive

Yes, Celgene (NASDAQ:CELG) is probably the riskiest big biotech on the planet. The company depends on one drug -- Revlimid -- for 64% of its revenue. It relies on three drugs for nearly 88% of its total revenue, more than any other major drugmaker. Market research firm EvaluatePharma ranked Celgene's pipeline risk, which it calculates by estimating cumulative sales … Συνεχίστε να διαβάζετε Why Celgene Is Looking Less Risky and More Attractive.

Novartis’ MS patent win also a win for Celgene’s impending MS drug: analyst

  After months of dark skies, the future suddenly looks sunny for Celgene's multiple sclerosis drug. Celgene's MS treatment ozanimod was in a race to hit the market before Novartis' MS drug Gilenya went off patent. However, the tides have turned after the patent office granted another nine years of exclusivity to Gilenya on Thursday. … Συνεχίστε να διαβάζετε Novartis’ MS patent win also a win for Celgene’s impending MS drug: analyst.

The 2018 pipeline report: Aspiring assets to keep an eye on

Looking ahead to 2018, the most promising products in pharma's pipeline will compete in a landscape that increasingly rewards big risks and places an emphasis on novel mechanisms. That comes with a catch. Consumers are more sensitive than ever to high prices, with more than 30 states introducing legislation on drug pricing. Given the current political … Συνεχίστε να διαβάζετε The 2018 pipeline report: Aspiring assets to keep an eye on.